Weekly News Update


*The Supreme Court on Thursday issued several decisions in criminal cases, including ones on the death penalty, testimony from children and jury selection. [NY Times]

*The divided 2nd Circuit said the federal government’s top law enforcers can be sued by former inmates who claim their civil rights were violated while jailed after the Sept. 11, 2001 attacks because they were Arab, Muslim or stereotyped that way. [Reuters]

*A cyclist who collided with a dog in New York’s Central Park cannot sue its owners, the state’s top court ruled on Tuesday, saying riders should be careful not to cross paths with animals that are a constant public presence. [AM New York]

*A Brooklyn man serving a 25-to-life bid for stabbing his ex-girlfriend to death is getting a new trial after an appeals court threw out his conviction. After two decades of appeals, the state Appellate Division granted Daryl Graham a new trial on the grounds of ineffective representation by Joel Medows, who “failed to take the minimal steps” to get his psychiatric records or have him evaluated by an expert in order to present a proper psychiatric defense. [NY Daily News]

*In a closely watched, long-running dispute over who gets custody of frozen embryos when the man and woman who created them disagree, an appeals court in Chicago ruled 2 to 1 last Friday that a woman whose fertility was destroyed by cancer treatment could use embryos she created with her ex-boyfriend, over his objections. [NY Times]

*A court system policy that prevented state Supreme Court justices from applying to stay on the bench past the age of 70 if they collected judicial pension benefits is illegal, a state appeals court unanimously ruled Thursday. [Times Union]

*A taxi kingpin who faced the bank seizure of up to 90 medallions got a break Monday when an appeals courts awarded him a temporary stay. [New York Post]

*The 2-1 decision by the U.S. Court of Appeals for the Federal Circuit made on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. [Reuters]